SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Myozyme

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2006.
Why 3/10
Myozyme is an already-approved, marketed drug with no pending regulatory decision, PDUFA date, or pivotal readout. It is a legacy product being actively replaced by Sanofi's own next-generation Pompe drug Nexviazyme. As a mature, declining asset within a diversified EUR 50B+ pharma company, there is no binary catalyst to drive a significant share-price move.
Actionable Insight NEUTRAL

Myozyme is a declining legacy asset being actively replaced by Sanofi's own next-gen Pompe drug Nexviazyme. The key near-term event to watch is whether Sanofi resolves the Waterford manufacturing issues (FDA warning letter from June 2026) that caused supply shortages in August 2026, and whether Nexviazyme wins FDA approval for infantile-onset Pompe (submission planned for H2 2026), which would further accelerate the switch away from Myozyme.

Price Chart

Loading chart...

Executive Summary

Myozyme (alglucosidase alfa, also marketed as Lumizyme) is an enzyme replacement therapy for Pompe disease, first approved by the FDA in 2006. Developed by Genzyme (a Sanofi subsidiary), it was the first treatment ever for Pompe disease and built a franchise that once peaked above EUR 1 billion annually. However, Myozyme is now a declining legacy product. Sanofi has launched a next-generation Pompe drug, Nexviazyme (avalglucosidase alfa), which is actively replacing Myozyme as patients switch to the newer therapy. In Q3 2026, Myozyme/Lumizyme revenue fell 15.6% year-over-year to EUR 105 million, while Nexviazyme generated EUR 211 million. The drug also faced supply disruptions in August 2026 after the FDA issued a Warning Letter in June 2026 to Sanofi's Waterford, Ireland manufacturing plant over quality and data integrity issues. As an approved, mature drug with no pending regulatory catalyst within a diversified EUR 50B+ pharma giant, Myozyme has limited standalone impact on Sanofi's share price.

How It Works

Myozyme is an enzyme replacement therapy for Pompe disease, a rare genetic disorder where patients lack an enzyme needed to break down glycogen (a stored sugar) in cells. The drug is a manufactured copy of the missing human enzyme (acid alpha-glucosidase). It is given as an intravenous infusion every two weeks, replacing the deficient enzyme and helping to prevent glycogen buildup that would otherwise damage muscles, including the heart and breathing muscles.

Trial Status

Myozyme/Lumizyme is FDA-approved and commercially marketed. Sanofi is transitioning patients to its next-generation Pompe drug Nexviazyme (avalglucosidase alfa), which completed a successful Phase 3 Baby-COMET trial in June 2026 for infantile-onset Pompe disease. Sanofi plans to submit for FDA approval in the second half of 2026.

The Two-Sided Case

▲ Bull Case3
Myozyme/Lumizyme remains the only FDA-approved enzyme replacement therapy for certain Pompe disease patient populations and continues to generate meaningful revenue (EUR 105 million in Q3 2026 alone), with no generic or biosimilar competition on the market.
The drug has a long-established safety and efficacy profile with over 20 years of real-world use. Sanofi's Genzyme division maintains a dominant position in Pompe disease treatment, with Myozyme and Nexviazyme together capturing the entire ERT market.
Sanofi's Q3 2026 earnings beat estimates and the company raised full-year guidance, demonstrating that the rare disease franchise (including Myozyme) remains profitable despite the ongoing transition to Nexviazyme.
▼ Bear Case3
Myozyme/Lumizyme revenue is in structural decline: Q3 2026 sales fell 15.6% to just EUR 105 million as patients switch to Sanofi's own next-gen drug Nexviazyme, which generated EUR 211 million in the same quarter.
The FDA issued a Warning Letter to Sanofi's Waterford, Ireland manufacturing plant (Genzyme Ireland) on June 22, 2026, citing significant data integrity and quality control failures. This triggered supply shortages of both Myozyme and Nexviazyme reported in August 2026, creating regulatory and operational overhang.
As a 20-year-old approved biologic, Myozyme faces no binary regulatory catalyst. It is a mature, declining product within a EUR 50B+ diversified pharma giant, so its individual performance has negligible impact on Sanofi's share price.

Upcoming Catalysts

  • Resolution of FDA Warning Letter (June 2026) for Waterford manufacturing plant and restoration of normal supply
  • Potential FDA submission and decision for Nexviazyme in infantile-onset Pompe disease (submission planned H2 2026)
  • Continued revenue decline trajectory as patient switching to Nexviazyme accelerates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 13

Hover a chip for the title
1 accessdata.fda.gov2 drugs.com3 en.wikipedia.org4 fda.gov5 statnews.com6 sanofi.com7 sanofi.com8 sanofi.com9 medicaldaily.com10 ema.europa.eu11 accessdata.fda.gov12 biotechreality.com13 healthcareinsights.vn